---
title: "China Resources Pharmaceutical issues RMB1 billion medium term notes"
url: "https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-medium-term-notes/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-07-22"
section: "Debt Financing"
tickers: "HKEX:3320"
source: "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0722/2026072200738.pdf"
summary: "A wholly owned subsidiary completed the first tranche of its 2026 medium term notes on 21 July 2026, at 1.53% per annum over 3 years."
---

By the aibio.space news desk.

Sources

- [China Resources Pharmaceutical Group Limited announcement (2026-07-22)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0722/2026072200738.pdf)

[3320](https://aibio.space/companies/china-resources-pharmaceutical/)

2026-07-22

# China Resources Pharmaceutical issues RMB1 billion medium term notes

Tickers [3320](https://aibio.space/companies/china-resources-pharmaceutical/)

A wholly owned subsidiary completed the first tranche of its 2026 medium term notes on 21 July 2026, at 1.53% per annum over 3 years.

## Key facts

- **Company**: China Resources Pharmaceutical Group Ltd. (HKEX: 3320)

- **News type**: Debt Financing

- **Primary source**: [China Resources Pharmaceutical Group Limited announcement (2026-07-22)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0722/2026072200738.pdf)

*The lower Manhattan skyline. CC0, via rawpixel. The picture shows the field, not the companies named.*

China Resources Pharmaceutical Group Limited said on July 22, 2026 that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, completed the issuance of the first tranche of medium term notes for 2026 in the PRC on 21 July 2026. The announcement refers to an earlier announcement dated 29 May 2026 about the proposed issuance.

The notes were issued in a principal amount of RMB1 billion, with a term of 3 years and a coupon rate of 1.53% per annum.

The proceeds will be used for replenishment of working capital, repayment of interest-bearing debts and other purposes that comply with applicable laws and regulations.

The announcement names no placement agent, underwriter or advisor for the notes. Shareholders and potential investors were told to take care when dealing in the company's securities.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

3320

China Resources Pharmaceutical Group Ltd.

HKEX · Hong Kong

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-medium-term-notes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "China Resources Pharmaceutical issues RMB1 billion medium term notes", 2026-07-22, https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-medium-term-notes/